- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.08. | Sionna cystic fibrosis drug fails key trial, removing threat to Vertex | ||
| 10.08. | Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal | ||
| 10.08. | Scribe's Benjamin Oakes on a rare IPO and bringing CRISPR to the masses | ||
| 10.08. | Regulatory operations: The overlooked half of submission readiness | ||
| 07.08. | 'Significant' demand for Revolution drug; Intellia pinpoints liver toxicity culprit | ||
| 07.08. | Latigo IPO raises nearly $350M for pain drug development | ||
| 06.08. | Replimune rebounds to win FDA approval of melanoma drug | ||
| 06.08. | Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M | ||
| 06.08. | Takeda approval ushers in new wave of sleep drugs | ||
| 06.08. | Erica Schwartz confirmed as next CDC director | ||
| 06.08. | With $263M, LifeMine unearths a new drug for organ transplants | ||
| 06.08. | FDA approves Moderna's mRNA flu vaccine | ||
| 05.08. | Attovia adds to biotech IPO momentum with $289M offering | ||
| 05.08. | Lilly climbs, Novo falls as obesity drug battle intensifies | ||
| 05.08. | Earnings roundup: Gilead's 'uncertain' future, Pfizer's crossroads and Merck's PCSK9 launch | ||
| 05.08. | A COPD drug from China draws $115M in venture funding | ||
| 04.08. | Vertex's biggest overhang: a rival 50 times smaller | ||
| 04.08. | Pfizer expands multibillion-dollar cost-cutting plan | ||
| 04.08. | J&J pharma leader to retire; Krystal slumps on gene therapy miss | ||
| 03.08. | An AstraZeneca-Bristol Myers megamerger? Wall Street isn't thrilled. | ||
| 03.08. | BioNTech taps Sobi executive Oelkers as its next CEO | ||
| 03.08. | Supernus, Individor merge to beef up brain drug portfolio | ||
| 31.07. | Novo setback casts doubt on a new way to treat heart disease | ||
| 31.07. | Sanofi to 'rebuild trust' with Regeneron; Apnimed adds to string of 'upsized' biotech IPOs | ||
| 30.07. | Replimune melanoma drug wins support of FDA panel |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.